2024-514152-32-00RecruitingPhase 1
A Study to Test How Safe, Effective and How the Body Responds to the Combination of Mosunetuzumab and Pirtobrutinib Together to Treat Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Source: EU CTIS (euclinicaltrials.eu) · Last updated 13 Jul 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (estimated)
- First submitted
- 10 Jun 2025
- Start date
- 6 Oct 2025
- Lead sponsor
- F. Hoffmann-La Roche AG
- Diseases
- Chronic lymphocytic leukaemia
- EU CT number
- 2024-514152-32-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 22
- 8 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (8)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitari Vall d'Hebron | Barcelona | Spain | Recruiting |
| Clinica Universidad de Navarra | Madrid | Spain | Recruiting |
| Clínica Universidad de navarra | Pamplona | Spain | Recruiting |
| University Hospital Of Clermont-Ferrand | Clermont-Ferrand | France | Recruiting |
| Oncopole Claudius Regaud | Toulouse | France | Recruiting |
| Pratia S.A. | Cracow | Poland | Recruiting |
| Uniwersytecki Szpital Kliniczny nr 4 w Lublinie | Lublin | Poland | Recruiting |
| Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu | Wroclaw | Poland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.